TheraRadar
← Back
Data updated: Jun 28, 2026

EMD SERONO

Biotech
OncologyNeurologyImmunology Execution: Fair

EMD SERONO is a biotechnology company focused on Oncology, Neurology, Immunology. Key products include BAVENCIO.

1982
Since
18
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules 5 Biologics

FDA Novel Drug Designations

(2017-2021)
2 Novel 2 Orphan 1 Breakthrough 2 Accelerated 2 Priority Review 1 Fast Track
See 2 novel approvals →
2021 TEPMETKO (TEPOTINIB HYDROCHLORIDE) Orphan · Priority Review · Accelerated
2017 BAVENCIO (AVELUMAB) Orphan · Breakthrough · Priority Review · Accelerated · Fast Track

EMD SERONO at a Glance

  • Fast trial execution (23 months median completion)

EMD SERONO's Recent FDA Approvals

New NDA/BLA approvals for EMD SERONO over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EMD SERONO's Therapeutic Areas

EMD SERONO's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 5 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 63%
3 drugs Phase 3: 12 Phase 2: 20 Phase 1: 47
Neurology 20%
1 drugs Phase 3: 7 Phase 2: 5 Phase 1: 5
Immunology 12%
0 drugs Phase 3: 2 Phase 2: 9 Phase 1: 2
Metabolic 2%
1 drugs
Gastroenterology 2%
0 drugs Phase 3: 1 Phase 1: 2

EMD SERONO's Top Competitors

EMD SERONO's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Immunology, Neurology, Metabolic
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Neurology

EMD SERONO Pipeline Snapshot

EMD SERONO has 112 active clinical programs from ClinicalTrials.gov — 22 Phase 3, 34 Phase 2 and 56 Phase 1.

22
Phase 3
34
Phase 2
56
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • BAVENCIO leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/7 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges